Stomach
Sacrosidase and your FAA medical
Enzyme
Other names: Sucraid
Wait
7 days
after the first dose (the FAA's MedGuide)
Two FAA documents give different waits. Both are below.
The FAA's MedGuide lists sacrosidase (Sucraid) as allowed, for congenital sucrase-isomaltase deficiency (CSID), with a wait of 7 days after the first dose and none after later doses or after the final dose, used as prescribed.
Track your medicationsCompare FAA documents: sacrosidaseWhat each of the two FAA documents says, in plain wordsOpen
The FAA's documents differ. The FAA's MedGuide gives sacrosidase (Sucraid) a wait of 7 days after the first dose. The FAA's CSID disposition table, updated 28 October 2026, names no waiting period; until then its Row A had the examiner verify a 7-day waiting period since starting sacrosidase (Sucraid). Both are current FAA documents, so neither is set aside.
Wait
- the FAA's CSID table names no waiting period
The MedGuide defines allowed as acceptable for use while performing flight or safety-related duties, provided the condition is stable/aeromedically acceptable and no adverse side effects are present, and says wait times are not determined solely by the medication: an extended observation period may be required to verify clinical stability of the condition.
The FAA's disposition table for congenital sucrase-isomaltase deficiency (CSID) names no waiting period: for CSID that is well-controlled with no medication side effects, it says ISSUE if the examiner can determine that the condition is under control, current medications are acceptable, and there are no symptoms that would interfere with flight or safety-related duties.
- 7 days after the first dose: ground observation
Show the FAA's words: sacrosidaseThe official FAA wording: four passages, each with its document and dateOpen
Generic: sacrosidase
Brand Name: Sucraid
Drug Class: Enzyme
Underlying Condition: Congenital sucrase-isomaltase deficiency (CSID)
Use: ALLOW
INITIAL Wait Time (after first dose): 7 days
SUBSEQUENT Dose Wait Time (after each dose): None
DISCONTINUATION Wait Time (after final dose): None
Frequency Use Limit: As prescribed
ALLOWED: The medication is acceptable for use while performing flight or safety-related duties, provided the condition is stable/aeromedically acceptable and no adverse side effects are present.
Underlying Condition: Evaluating medication use requires considering the impact of safety of flight from both the medication and underlying condition. Wait times are not determined solely by the medication; an extended observation period may be required to verify clinical stability of the condition.
A. Well-controlled AND No medication side effects If the AME can determine that the condition is under control, current medications are acceptable, and no symptoms that would interfere with flight or safety-related duties. ISSUE